Using an RNA-based drug delivered to multiple myeloma blood cancer cells by targeted lipid nanoparticles, researchers at Tel Aviv University (TAU) destroyed 90% of the cells under laboratory conditions and 60% of the cells in human tissues. The researchers developed lipid-based nanoparticles, similar to those used in the COVID-19 vaccine, containing RNA molecules that silence the gene...